Literature DB >> 24211191

CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.

Rania Elakoum1, Guillaume Gauchotte1, Abderrahim Oussalah1, Marie-Pierre Wissler1, Christelle Clément-Duchêne1, Jean-Michel Vignaud1, Jean-Louis Guéant2, Farès Namour3.   

Abstract

CARM1 and PRMT1 are 2 Protein Arginine Methyl Transferases (PRMT) dysregulated in cancer. CARM1 function is contradictory and depicted as facilitating proliferation or differentiation. PRMT1 is required for cell proliferation. CARM1 and PRMT1 cooperate for gene regulation. We report that CARM1 and PRMT1 are significantly overexpressed in 60 patients with Non-Small Cell Lung Carcinomas (NSCLC). CARM1 and PRMT1 correlated in healthy but not tumor tissue. Their levels of expression in tumor tissue were proportional to their levels of expression in the counterpart healthy tissue. Only CARM1 expression was found to be correlated with tumor differentiation and neither CARM1 nor PRMT1 expression was correlated with survival. Accordingly, CARM1 and PRMT1 are overexpressed in 2 NSCLC cell lines, A549 and H1299. Targeting PRMT1 with siRNA reduced proliferation, by decreasing cell growth and inhibiting soft agar colony formation, and promoted differentiation, by increasing the epithelial markers cytokeratin 7 and 8 and decreasing Neuromedin B receptor, which binds a mitogenic factor. siCARM1 yielded similar consequences but the conditions with siCARM1 reflected inhibition of both CARM1 and PRMT1. Together these results suggest that CARM1 and PRMT1 are involved in proliferation in lung cancer with no hierarchy of one protein over the other. The fact that CARM1 targeting suppresses PRMT1 in addition to CARM1 reinforces the functional importance of CARM1/PRMT1 interaction.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CARM1; Lung cancer; PRMT1; Proliferation; siRNA

Mesh:

Substances:

Year:  2013        PMID: 24211191     DOI: 10.1016/j.biochi.2013.10.021

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  28 in total

1.  Design and synthesis of selective, small molecule inhibitors of coactivator-associated arginine methyltransferase 1 (CARM1).

Authors:  H Ü Kaniskan; M S Eram; J Liu; D Smil; M L Martini; Y Shen; V Santhakumar; P J Brown; C Arrowsmith; M Vedadi; J Jin
Journal:  Medchemcomm       Date:  2016-07-13       Impact factor: 3.597

Review 2.  Inhibitors of Protein Methyltransferases and Demethylases.

Authors:  H Ümit Kaniskan; Michael L Martini; Jian Jin
Journal:  Chem Rev       Date:  2017-03-24       Impact factor: 60.622

3.  Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.

Authors:  Bolag Altan; Takehiko Yokobori; Munenori Ide; Erito Mochiki; Yoshitaka Toyomasu; Norimichi Kogure; Akiharu Kimura; Keigo Hara; Tuya Bai; Pinjie Bao; Masaki Suzuki; Kyoichi Ogata; Takayuki Asao; Masahiko Nishiyama; Tetsunari Oyama; Hiroyuki Kuwano
Journal:  Gastric Cancer       Date:  2015-10-15       Impact factor: 7.370

4.  High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1.

Authors:  Bing Hu; Xin Li; Ling Chen; Zhongliang Liu
Journal:  Lung       Date:  2020-02-07       Impact factor: 2.584

5.  A Direct Assay for Measuring the Activity and Inhibition of Coactivator-Associated Arginine Methyltransferase 1.

Authors:  Yurui Zhang; Matthijs J van Haren; Nils Marechal; Nathalie Troffer-Charlier; Vincent Cura; Jean Cavarelli; Nathaniel I Martin
Journal:  Biochemistry       Date:  2022-05-17       Impact factor: 3.321

6.  Purification and Identification of Natural Inhibitors of Protein Arginine Methyltransferases from Plants.

Authors:  Zhengxin Wang; Ling Xiong; Quanbo Xiong
Journal:  Mol Cell Biol       Date:  2022-03-21       Impact factor: 5.069

7.  A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.

Authors:  Mohammad S Eram; Yudao Shen; Magdalena Szewczyk; Hong Wu; Guillermo Senisterra; Fengling Li; Kyle V Butler; H Ümit Kaniskan; Brandon A Speed; Carlo Dela Seña; Aiping Dong; Hong Zeng; Matthieu Schapira; Peter J Brown; Cheryl H Arrowsmith; Dalia Barsyte-Lovejoy; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  ACS Chem Biol       Date:  2015-12-08       Impact factor: 5.100

Review 8.  Targeting Epigenetics in Cancer.

Authors:  Richard L Bennett; Jonathan D Licht
Journal:  Annu Rev Pharmacol Toxicol       Date:  2017-10-06       Impact factor: 13.820

Review 9.  Non-Histone Arginine Methylation by Protein Arginine Methyltransferases.

Authors:  Ayad A Al-Hamashi; Krystal Diaz; Rong Huang
Journal:  Curr Protein Pept Sci       Date:  2020       Impact factor: 3.272

10.  FEN1 inhibitor synergizes with low-dose camptothecin to induce increased cell killing via the mitochondria mediated apoptotic pathway.

Authors:  Ting Wu; Hongqiao Zhu; Miaomiao Zhang; Yuling Sun; Yongjing Yang; Lili Gu; Jing Zhang; Dan Mu; Congye Wu; Zhigang Hu; Longwei Jiang; Shaochang Jia; Ying Zhang; Lingfeng He; Fei-Yan Pan; Zhigang Guo
Journal:  Gene Ther       Date:  2021-01-07       Impact factor: 4.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.